Alder BioPharmaceuticals (NASDAQ:ALDR) resumed with Neutral rating and $14 (22% upside) price target at Credit Suisse. Shares up 1% premarket.
HMS Holdings (NASDAQ:HMSY) resumed with Outperform rating and $40 (19% upside) price target at Credit Suisse.
DaVita (NYSE:DVA) resumed with Neutral rating and $62 (18% upside) price target at Goldman Sachs. Shares up 1% premarket.
Intersect ENT (NASDAQ:XENT) upgraded to Market Perform with a $20 (5% downside risk) price target at Northland Capital Markets.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.